Literature DB >> 20459570

Expression of the extracellular matrix protein periostin in liver tumours and bile duct carcinomas.

Marc-Oliver Riener1, Florian R Fritzsche, Christopher Soll, Bernhard C Pestalozzi, Nicole Probst-Hensch, Pierre-Alain Clavien, Wolfram Jochum, Alex Soltermann, Holger Moch, Glen Kristiansen.   

Abstract

AIMS: To study the relevance of periostin, known to be involved in epithelial-mesenchymal transition (EMT), in hepatocellular and bile duct cancer. METHODS AND
RESULTS: Immunohistochemical periostin expression was semiquantitatively analysed in normal liver tissue (n = 20), hepatocellular carcinoma (HCC; n = 91), liver-cell adenoma (n = 9), focal nodular hyperplasia (n = 13) and bile duct carcinomas (BDC; n = 116) using tissue microarrays. Normal bile ducts, gallbladder epithelium and hepatocytes showed weak cytoplasmic periostin expression. In HCC, there was strong epithelial periostin expression in 19/91 (20.9%) and strong stromal periostin expression in 10/91 cases (11%). Epithelial expression in tumour cells was significantly associated with a higher tumour grade (P < 0.05) and hepatitis B virus infection (P = 0.007). Importantly, there was no strong periostin expression in benign liver tumours. Strong stromal periostin expression was detected in 78/116 (67.2%) BDC and strong epithelial expression in 39/116 (33.6%) BDC. pT stage, differentiation grade and proliferation rate in primary BDC were independent of periostin expression. Epithelial periostin expression was associated with reduced overall survival on univariate and multivariate analysis.
CONCLUSIONS: The EMT protein periostin is expressed in the stroma and epithelium of a subset of BDC and HCC. Epithelial periostin expression is a marker for malignant transformation of hepatocytes and a novel prognostic marker in BDC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20459570     DOI: 10.1111/j.1365-2559.2010.03527.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  26 in total

Review 1.  [Diagnosis of tumours of the liver and the biliary tract: new tissue and serum markers].

Authors:  M-O Riener
Journal:  Pathologe       Date:  2011-11       Impact factor: 1.011

Review 2.  Hepatocellular Carcinoma: Etiology and Current and Future Drugs.

Authors:  Aastha Jindal; Anusha Thadi; Kunwar Shailubhai
Journal:  J Clin Exp Hepatol       Date:  2019-01-25

3.  Relevance of periostin splice variants in renal cell carcinoma.

Authors:  Laura Morra; Markus Rechsteiner; Silvia Casagrande; Van Duc Luu; Roger Santimaria; Pierre A Diener; Tullio Sulser; Glen Kristiansen; Peter Schraml; Holger Moch; Alex Soltermann
Journal:  Am J Pathol       Date:  2011-07-18       Impact factor: 4.307

4.  High-level expression of periostin is closely related to metastatic potential and poor prognosis of hepatocellular carcinoma.

Authors:  Yang Lv; Wei Wang; Wei-Dong Jia; Qi-Kai Sun; Jian-Sheng Li; Jin-Liang Ma; Wen-Bin Liu; Hang-Cheng Zhou; Yong-Sheng Ge; Ji-Hai Yu; Hong-Hai Xia; Ge-Liang Xu
Journal:  Med Oncol       Date:  2012-12-30       Impact factor: 3.064

Review 5.  Periostin in intrahepatic cholangiocarcinoma: pathobiological insights and clinical implications.

Authors:  Alphonse E Sirica; Jorge A Almenara; Chao Li
Journal:  Exp Mol Pathol       Date:  2014-10-28       Impact factor: 3.362

Review 6.  Intestinal myofibroblasts: targets for stem cell therapy.

Authors:  R C Mifflin; I V Pinchuk; J I Saada; D W Powell
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-01-20       Impact factor: 4.052

7.  Synergistic effect of pro-inflammatory TNFα and IL-17 in periostin mediated collagen deposition: potential role in liver fibrosis.

Authors:  Suneetha Amara; Karina Lopez; Babak Banan; Sade-Kemi Brown; Margaret Whalen; Elbert Myles; Michael T Ivy; Terrance Johnson; Kevin L Schey; Venkataswarup Tiriveedhi
Journal:  Mol Immunol       Date:  2014-11-11       Impact factor: 4.407

8.  Periostin is up-regulated in high grade and high stage prostate cancer.

Authors:  Verena Tischler; Florian R Fritzsche; Peter J Wild; Carsten Stephan; Hans-Helge Seifert; Marc-Oliver Riener; Thomas Hermanns; Ashkan Mortezavi; Josefine Gerhardt; Peter Schraml; Klaus Jung; Holger Moch; Alex Soltermann; Glen Kristiansen
Journal:  BMC Cancer       Date:  2010-06-09       Impact factor: 4.430

Review 9.  The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer.

Authors:  Silvia Affo; Le-Xing Yu; Robert F Schwabe
Journal:  Annu Rev Pathol       Date:  2016-12-05       Impact factor: 23.472

10.  Periostin: a promising target of therapeutical intervention for prostate cancer.

Authors:  Chuanyu Sun; Xiaojun Zhao; Ke Xu; Jian Gong; Weiwei Liu; Weihong Ding; Yuancheng Gou; Guowei Xia; Qiang Ding
Journal:  J Transl Med       Date:  2011-06-30       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.